[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-aortic-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-aortic-aneurysm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,47,76,105,129,160,183,216,242,263,283,313,334,351,374],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630092","phase-1-heart-pilot-randomized-controlled-trial-100630092",false,"NCT07483177","HEART: Pilot Randomized Controlled Trial","Hemodynamic Effects Of Aldosterone Receptor Blockade In Degenerative Thoracic Aortic Aneurysm: A Pilot Randomized Controlled Trial (HEART: Pilot RCT)","Inclusion Criteria\n\n1. Adults ≥ 18 years old with dTAA of the aortic root and\u002For ascending aorta exceeding the upper limit of normal for age, sex, and body surface area (≥ 4.0 cm as an example of a common threshold; but age, sex and body size-specific thresholds have been established for the aortic root24 and ascending aorta25);\n2. no antihypertensive use or stable antihypertensive regimen ≥ 4 weeks;\n3. eGFR ≥ 50 mL\u002Fmin\u002F1.73 m²;\n4. serum potassium ≤ 5.1 mmol\u002FL;\n5. ability to provide informed consent.\n\nExclusion Criteria\n\n1. Heritable aortopathies (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndromes; familial TAA, genetically-proven TAA);\n2. bicuspid aortic valve;\n3. inflammatory aortitis,\n4. prior aortic surgery, endovascular repair, or acute aortic syndrome;\n5. permanent atrial fibrillation\u002Fflutter;\n6. major peripheral artery disease affecting the carotids, iliacs and\u002For external femoral arteries precluding cfPWV measurement;\n7. current use of spironolactone, eplerenone or finererone;\n8. pregnancy or lactation.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.",[27],"Thoracic Aortic Aneurysm",[29,30,31,32,33],"spironolactone","aortic aneurysm","thoracic aortic aneurysm","aortic stiffness","arterial stiffness","RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2026-05-25",{"date":42,"type":20},"2028-05",{"name":44,"class":45},"Mayo Clinic","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100636337","mba-early-feasibility-study-100636337","NCT07564375","MBA Early Feasibility Study","Early Feasibility Study of the GORE® Multibranch Arch Endoprosthesis (MBA Device)","Inclusion Criteria:\n\nThe subject is \u002F has:\n\n1. Thoracic pathologies with involvement of the arch branch vessels, that are compatible with the treatment requirements of the MBA device, and meeting any of the following criteria:\n\n   a) Aneurysm and Isolated Lesions: i. Fusiform aneurysm (≥ 55 mm or documented growth rate \\> 0.5 cm\u002Fyear). ii. Saccular aneurysm (no diameter criteria). iii. Pseudoaneurysms (\\> 30 days post-surgery, no diameter criteria). iv. Penetrating Aortic Ulcers (PAUs) without intramural hematoma (IMH) (no diameter criteria).\n\n   b) Aortic dissection: i. Uncomplicated and high-risk chronic de novo (\\> 90 days) Type B aortic dissection with primary entry tear in the arch or descending thoracic aorta.\n\n   ii. Residual aortic dissection following surgical repair of Type A aortic dissection requiring treatment (\\> 30 days post-treatment).\n\n   iii. Proximal extension of prior endovascular repair (\\> 30 days post-treatment and \\> 90 days post-dissection) of a Type B dissection requiring treatment.\n\n   iv. Pseudoaneurysms, following open surgical repair of a Type A dissection (\\> 30 days post-surgery, no diameter criteria).\n2. Anatomic compatibility with MBA device and other devices required for proximal or distal extensions based on Gore's review.\n\n   1. Adequate vascular access via transfemoral or retroperitoneal approach.\n   2. Appropriate vascular access to allow for through-wire access to the brachiocephalic artery, LCCA, and LSA.\n   3. Proximal Aortic Landing Zone:\n\n   i. Landing zone is native aorta, surgical graft, or previously implanted GORE thoracic stent graft.\n\nii. Landing zone diameter between 27 mm - 48 mm. iii. Acceptable ascending aorta outer curvature length for the required MBA device.\n\n1. Proximal segment length (length from distal edge of brachiocephalic artery to distal edge of the most distal coronary artery) must be ≥ 2 cm longer than the \"AC Proximal End to BCA Portal Length\" for the selected Aortic Component or ≥ 3 cm if the landing zone is \\> 42 mm.\n2. For patients with patent bypass graft from the ascending aorta, proximal extent of landing zone must be ≥ 1 cm distal to the bypass graft.\n\niv. Lesion location is ≥ 2 cm distal to the most distal coronary artery ostium. v. For patients with an existing transcatheter aortic valve replacement (TAVR) there must be a sufficient proximal landing zone to avoid interference with the required MBA device (including any proximal extensions with the ASG device).\n\nvi. Proximal landing zone must be ≥ 2 cm in the ascending aorta.\n\n1. For patients with prior replacement of the ascending aorta and \u002F or aortic arch by surgical graft, there must be ≥ 2 cm overlap of MBA device and previously implanted graft.\n2. For patients with a de novo aortic dissection, the primary entry tear must be located ≥ 2 cm distal to the proximal extent of the MBA device (including any proximal extensions) and the proximal edge of the stent graft must land in non-dissected aorta.\n\n   vii. Landing zone cannot be aneurysmal, heavily calcified, or heavily thrombosed.\n\n   d) Branch Vessel Landing Zone: i. Length of ≥ 2.5 cm proximal to first major branch vessel. ii. Target branch vessel inner diameter of 11-18 mm for the 12 mm portal, and 6-15 mm for the 8 mm portal.\n\n   iii. Target branch vessel landing zone must be in native aorta that cannot be heavily calcified, or heavily thrombosed.\n\n   iv. All three arch target vessels must have appropriate anatomy for cannulation (including through-wire access) and treatment with MBA branch components.\n\n   e) Distal Aortic Landing Zone (aneurysms and isolated lesions only): i. Outer curvature length must be ≥ 2 cm proximal to the celiac artery. ii. Aortic inner diameters between 16-42 mm. iii. Landing zone cannot be aneurysmal, heavily calcified, or heavily thrombosed.\n\n   iv. Landing zone in native aorta, surgical graft, or previously implanted GORE thoracic stent graft.\n3. Age ≥ 18 years at time of informed consent signature.\n4. Informed Consent Form (ICF) signed by the subject or legally authorized representative (LAR), according to local regulation.\n5. Agrees to comply with protocol requirements, including imaging and five year (60 month) follow-up.\n6. Considered high-risk for open surgical repair by meeting one or more of the following criteria:\n\n   1. ≥ 75 years of age\n   2. Previous median sternotomy\n   3. Documented identification of other subject-specific risk factors (e.g., medical history, active medical diagnosis) by a study investigator and an experienced open ascending and \u002F or aortic arch surgeon (e.g., cardiothoracic surgeon).\n7. Considered high-risk for surgical debranching by meeting one or more of the following criteria:\n\n   1. Prior neck surgery or radiation\n   2. Neck anatomy \u002F body habitus impeding carotid access or safe bypass tunneling\n   3. Dysphagia\n   4. Elevated risk for post-operative infection (e.g., malnutrition, uncontrolled diabetes (hemoglobin A1c \\> 9%), current treatment with immunosuppressant therapy or chemotherapy)\n   5. Reduced pulmonary function (e.g., severe chronic obstructive pulmonary disease (COPD), current or anticipated tracheostomy)\n   6. Clinical Frailty Scale score 6-7\n   7. Documented identification of other subject-specific risk factors which would pose high risk for surgical debranching (e.g., medical history, active medical diagnosis) by a study investigator\n\nExclusion Criteria:\n\nThe subject is \u002F has:\n\n1. De novo Type A dissection\n2. Requires immediate treatment.\n3. Arch vessels with dissection extending into the intended landing zones.\n4. Anticipated need for coronary or aortic valve intervention within one year post-treatment.\n5. Any aortic valve repair or replacement including transcatheter aortic valve replacement (TAVR) or coronary artery intervention within 30 days prior to treatment.\n6. Complex percutaneous coronary intervention (PCI) within 30 days prior to treatment.\n7. Open chest surgical repair within 30 days prior to treatment.\n8. Any open or interventional repair of either carotid artery within 30 days prior to treatment.\n9. Presence of Intramural Hematoma (IMH) in landing zones.\n10. Prosthetic heart valve in the aortic position that precludes safe delivery of any study device.\n11. Aortic insufficiency (AI) grade 3 or greater.\n12. Previous endovascular repair with a non-Gore device that would interfere with or result in contact with planned repair.\n13. Concomitant vascular disease, including disease associated with the great and upper extremity vessels, requiring treatment that is not planned for index endovascular procedure.\n14. Any stroke or MI within 90 days prior to treatment.\n15. Presence of protruding and \u002F or irregular thrombus and \u002F or atheroma in the ascending aorta or aortic arch or any other factor that could increase the risk of stroke based on Gore's review.\n16. Any chronic condition that is not well controlled and that is known to increase stroke risk.\n17. Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome (EDS)).\n18. Participation in investigational drug or medical device study within one year of enrollment unless approved by the sponsor.\n19. Known medical, social, or psychological issues that the Investigator believes may interfere with treatment or follow-up, such as a history of drug abuse within one year of treatment.\n20. Pregnant at time of procedure or planning to become pregnant within the first 12-months of participation in the study.\n21. Active infected aorta, mycotic aneurysm.\n22. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).\n23. Renal failure, defined as patients with an estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 (mL\u002Fmin\u002F1.73 m2) or currently requiring dialysis.\n24. Life expectancy \\\u003C12 months.\n25. Known sensitivities or allergies to the device materials.\n26. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.\n27. Body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta.\n28. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin or a history of a hypercoagulability disorder and \u002F or state.\n29. Severe Congestive Heart Failure (CHF) (New York Heart Association (NYHA) functional class IV).\n30. Acute Coronary Syndrome (ACS) including unstable angina.",{"count":55,"type":20},20,[57],"NA","The MBA 25-04 study is a prospective, multicenter, non-randomized, single-arm, early feasibility study designed to assess the initial safety of the MBA device through five years following the index endovascular procedure.",[27,60,61,62],"Penetrating Aortic Ulcers (PAUs)","Thoracic Aortic Dissection","Pseudoaneurysm",[64],"MBA 25-04","NOT_YET_RECRUITING","2026-05-27",{"date":68,"type":38},"2026-06-01",{"date":70,"type":20},"2026-09",{"date":72,"type":20},"2034-11",{"name":74,"class":75},"W.L.Gore & Associates","INDUSTRY",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100469652","incidence-of-major-complication-in-case-of-thoracic-aortic-aneurysm-100469652","NCT05395598","Incidence of Major Complication in Case of Thoracic Aortic Aneurysm","Predicting Moderate Thoracic Aortic Aneurysm Evolution: a Longitudinal Study of Systemic Factors in Patients Free of Connective Tissue Disease. .","MOTAAR","Inclusion Criteria:\n\n* Documentation of an aortic root aneurysm \\> 40 mm\n* Agreement to participate to a longitudinal study and available for a 5 years follow-up\n\nExclusion Criteria:\n\n* Presence of comorbidities or pathology with a prognosis of less than 1 year\n* Personal or family history of genetically documented elastic tissue disease or patient meeting the GAND clinical criteria suggestive of Marfan disease\n* High-grade mitra-aortic valve disease, even if asymptomatic\n* Unbalanced hypertension ≥ 180\u002F110 mmHg\n* Aneurysm (regardless of thoracic or abdominal location) ≥ 50 mm\n* Aneurysm (regardless of thoracic or abdominal location) with documented progression of more than 5 mm over one year\n* History of aortic surgery or endovascular intervention and history of type B aortic dissection of medical treatment\n* Renal insufficiency on dialysis, or GFR\\\u003C 30 ml\u002Fmn (CKD-EPI)","45 Years","80 Years",{"count":87,"type":20},320,"OBSERVATIONAL","Thoracic aneurysm is a silent disease with a potential mid-term high risk of death or major complications. Few data are available on the real incidence of major complications in case of small and moderate thoracic aneurysm. Different factors are supposed to increase the risk of aortic enlargement as high blood pressure and sleep disorder breathing. The modality of imaging and clinical follow-up are well defined. In this prospective observational study, the aim to assess the incidence of of major complications during follow-up in a population of patients with a small or moderate thoracic aneurysm. The study will also try to identify systemic factors influencing aneurysm evolution.",[27],[92,93,94,95],"Thoracic aortic aneurysm","Incidence","nocturnal hypertension","Sleep apnea","2026-05-14",{"date":98,"type":38},"2026-05-15",{"date":100,"type":38},"2024-04-18",{"date":102,"type":20},"2031-10",{"name":104,"class":45},"University Hospital, Lille",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100381427","terumo-aortic-global-endovascular-registry-100381427","NCT04246463","Terumo Aortic Global Endovascular Registry","A Global Post Market Evaluation of Terumo Aortic Endovascular Grafts","TiGER","Inclusion Criteria:\n\n* Minimum age as per local regulations\n* Indication for aortic endovascular repair with an approved or CE marked by a Regulatory body or custom-made Terumo Aortic Endovascular graft\n* Ability to provide informed consent\n\n  o Emergent cases (typically younger patients with traumatic injuries) are not excluded if there is IRB\u002FEC agreement to allow consent after intervention (i.e. consent to study participation, not to treatment) or use of a Legally Authorized Representative (LAR).\n* Willingness to comply with the registry protocol\n* Willingness to adhere to follow-up visits Note: Patients currently enrolled and actively participating within the TREO registry (IP-0020-16) can have their data migrated from TREO to the TiGER registry where local EC approval has been obtained and the patient has been reconsented to TiGER for longer follow-up.\n\nExclusion Criteria:\n\nPatient is unable or unwilling to comply with the study follow-up regime. Patient is contraindicated per the IFU, or has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving treatment as well as the procedures and evaluations pre and post procedure.",{"count":114,"type":20},1000,"Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.",[117,27,118],"Abdominal Aortic Aneurysm","Surgery","2026-03-10",{"date":121,"type":38},"2026-03-13",{"date":123,"type":38},"2019-12-17",{"date":125,"type":20},"2030-11",{"name":127,"class":75},"Vascutek Ltd.",58,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100541926","antibacterial-tactics-based-on-presepsin-level-in-thoracic-aorta-surgery-patients-100541926","NCT06336213","Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients","Changes in Antibacterial Therapy Based on Perioperative Dynamics of Presepsin During Reconstructive Thoracic Aorta Surgery","Inclusion Criteria:\n\nThoracic aorta aneurysm\u002Fdissection\n\nExclusion Criteria:\n\nBlood sample hemolysis","75 Years",{"count":19,"type":20},[57],"According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.",[141,142,27,61],"Aortic Aneurysm and Dissection","Cardiac Valve Disease",[144,145,146,147,148,30,149,150],"biomarkers","presepsin","complications","aortic arch","aorta","ascending aorta","cardiac surgery","2026-01-28",{"date":153,"type":38},"2026-01-29",{"date":155,"type":38},"2024-01-23",{"date":157,"type":20},"2027-02-15",{"name":159,"class":45},"Petrovsky National Research Centre of Surgery",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":46},"100419891","b-safer-branched-stented-anastomosis-frozen-elephant-trunk-repair-100419891","NCT04747626","B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair","B-SAFER","Inclusion Criteria:\n\n1. At least 18 years of age\n2. Subject is willing and able to give written informed consent to participate in the study or the subject's legally authorized representative has given written informed consent for the subject to participate in the study.\n3. Expected life expectancy of greater than two years after repair\n4. Subject has aortic pathology and requires repair or replacement of multiple damaged or diseased segments of the thoracic aorta (at least one of the following condition): Thoracic aortic aneurysm considered at increased risk for rupture or complications, Acute aortic dissection requiring urgent repair, Congenital aortic disease requiring repair\n\nExclusion Criteria:\n\n1. Subject is unfit for open surgical repair involving circulatory arrest\n2. Subject is comatose or suffering from irreversible severe brain malperfusion\n3. Subject has known sensitivity to components of the devices\n4. Subject has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure\n5. Subject is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study\n6. Subject has an uncorrectable bleeding anomaly\n7. Subject has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post- procedure\n8. Subject is pregnant",{"count":168,"type":20},590,[57],"A prospective, single-center, non-blind, non-randomized safety and feasibility study of the hybrid repair of thoracic aortic pathologies requiring repair of the aortic arch proximal to the origin of innominate artery.",[27,172,173],"Aortic Dissection","Congenital Aortic Anomaly","2025-10-07",{"date":176,"type":38},"2025-10-09",{"date":178,"type":38},"2021-03-25",{"date":180,"type":20},"2030-12-31",{"name":182,"class":45},"Eric Roselli, M. D.",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":46},"100545064","using-the-ehr-to-advance-genomic-medicine-across-a-diverse-health-system-100545064","NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System","Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosed with one of the study conditions\n\nExclusion Criteria:\n\n* Under 18 years of age\n* not diagnosed with one of the study conditions",{"count":114,"type":20},[57],"Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and\u002For patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.",[194,195,196,197,198,199,200,201,202,27],"Genetic Predisposition","Paraganglioma","Pheochromocytoma","ALS","Parkinson Disease","Polyneuropathies","Frontotemporal Dementia","Alzheimer Disease","Cardiomyopathy Non-ischemic",[204,205,206],"Genetic testing","Genomic medicine","Electronic health record","2025-07-16",{"date":209,"type":38},"2025-07-20",{"date":211,"type":38},"2024-06-10",{"date":213,"type":20},"2027-06-30",{"name":215,"class":45},"University of Pennsylvania",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100576519","impact-of-right-atrial-occlusion-on-tevar-outcomes-100576519","NCT06786351","Impact of Right Atrial Occlusion on TEVAR Outcomes","Impact of Right Atrial Occlusion on TEVAR Outcomes: A Prospective Cohort Study","Inclusion Criteria:\n\n* age 18 years or older\n* thoracic endovascular aortic repair\n* right atrial balloon occlusion for reduction or elimination of aortic impulse\n* endograft deployment in landing zones 0-3\n\nExclusion Criteria:\n\n* age 18 years or younger\n* non-thoracic endovascular aortic repair\n* reduction or elimination of aortic impulse using technique other than right atrial balloon occlusion\n* endograft deployment in landing zones 4 and beyond",{"count":224,"type":20},100,"Though the application of thoracic endovascular aortic repair (TEVAR) for treatment of aortic pathology is expanding, there remains a gap in the literature examining how intraoperative \"reduction or elimination of aortic impulse\" (REAI) techniques, in particular the use of right atrial occlusion, may impact patient important clinical outcomes. This study aims to provide prospective data from a large cohort of TEVAR patients to explore clinical outcomes following TEVAR procedures and, specifically, whether right atrial occlusion has significant impact on clinical outcomes, as compared to other REAI techniques. The results from this study may inform future perioperative TEVAR practices and improve TEVAR patient outcomes.",[27,61,227],"Thoracic Aorta Abnormality",[229,230,231,232],"right atrial balloon occlusion","thoracic endovascular aortic repair","stent graft repair","reduction of elimination of aortic impulse","2025-06-25",{"date":235,"type":38},"2025-06-29",{"date":237,"type":20},"2025-09-01",{"date":239,"type":20},"2029-01-31",{"name":241,"class":45},"University of Calgary",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100377677","effects-of-exercise-on-thoracic-aneurysms-100377677","NCT04197648","Effects of Exercise on Thoracic Aneurysms","The Effect of Exercise on Thoracic Aortic Aneurysm and Blood Pressure Control.","EXTRA","Inclusion Criteria:\n\n* 18 years and older\n* Have an interest in participating in a supervised exercise training program\n* Aortic diameter between 3,5 and 5 cm\n\nExclusion Criteria\n\n* Glomerular filtration rate below 30 mL\u002Fmin\u002F1.73m²\n* Aortic diameter greater than or equal to 5.1 cm\n* Progression of aortic diameter greater than or equal to 0.5 cm per year\n* Allergy to iodine\n* Aortic valve bicuspidy\n* History of aortic surgery or cardiac surgery\n* Presence of an aortic dissection, penetrating aortic ulcer, or intra-mural hematoma of the aorta\n* Presence of Marfan syndrome or other genetic and\u002For congenital disease explaining the thoracic aortic aneurysm\n* History of stroke\n* Presence of peripheral artery disease\n* History and\u002For presence of aortitis\n* Known diagnosis of temporal arteritis or rheumatoid arthritis\n* Presence of a pacemaker\n* Major cognitive limitation that may affect adherence to visits\n* Musculoskeletal limitation that restricts participation in the training program",{"count":251,"type":20},30,[57],"Thoracic aneurysm incidence is estimated to 4.5 cases per 100 000. The manifestation as well as natural history of thoracic aneurysm depend on many factors such as its localisation, its diameter, presence of collagen disease and family history. For the ascendant aortic aneurysm, it is often linked to a degeneration of the media arterial layer of the arterial wall. The media degeneration is cause by the degeneration of the elastic fibres, which lead to a weakening of the arterial wall accompanied with dilation. This process is often due to age and is accelerated by high blood pressure. Amongst the numerous factors causing the aneurysm, the investigators find: hypertension, aortic bicuspid valve, smoking, atherosclerosis, trauma and genetic predisposition. The average growth rate of thoracic aneurysm is 0.1-0.2 cm\u002Fyear. The risk of rupture is associated to the size of the aneurysm as well as patient's symptoms. The ruptures and dissections rates are accounted for 2-3\u002Fyear for thoracic aneurysm between 5.5-6.0 cm in diameter. The patients are often limited in their daily life activities considering their concern and risk of rupture and\u002For dissect. The effects of exercise on the progression of the aneurysm dilation in patients with thoracic ascendant aortic aneurysm are unknown. It is well known that high blood pressure is a risk factor for rupture of the aortic aneurysm. Many studies have demonstrated the benefits of physical exercise regarding the lowering impact of blood pressure in a cardiac hypertensive population.\n\nAt 3 and 6 months of the intervention, the subjects in the exercise group will have: 1) a lowered blood pressure at rest and during exercise, 2) maintenance\u002F improvement of muscle strength, 3) improvement of aerobic exercise capacity (VO2max), and 4) aortic dilation that remained stable or comparable to the control group.\n\nThe research objective is to measure and compare to a control group, the effects of an exercise program on the following parameters: blood pressure response at rest and during exercise, as well as the VO2max at 3 and 6 months time of the intervention.\n\nThis randomised and prospective study will take place at the \" Institut Universitaire de Cardiologie et de Pneumologie du Québec (IUCPQ) \" and will include patients who have a non-surgical ascendant thoracic aortic aneurysm (ATAA). The selected subjects will be randomised into two groups: 1) exercise group (n=15), and 2) control group (n=15). Both groups will be met prior to the intervention (baseline) and at 3 and 6 months time of the intervention, and measures described below will be recorded.",[27],{"date":235,"type":38},{"date":257,"type":38},"2025-06-10",{"date":259,"type":20},"2027-04",{"name":261,"class":45},"Laval University",2,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":46},"100543264","genetic-architecture-of-acute-aortic-syndromes-and-aortic-aneurysm-100543264","NCT06353607","Genetic Architecture of Acute Aortic Syndromes and Aortic Aneurysm.","Inclusion Criteria:\n\n* All adult patients \\> 18 years who underwent surgery for aAD or TAA intervention at the University Hospital Basel, starting in 2015.\n* All patients who will undergo surgery for aAD or TAA at the University Hospital Basel, beginning in 2024.\n\nExclusion Criteria:\n\n* Patients will be excluded if they are not able or not willing to provide informed consent.\n* Patients with diagnosed heritable vascular disorders, such as Marfan syndrome, Turner Syndrome, Loeyes Dietz and Ehlers-Danlos syndrome.",{"count":270,"type":20},730,"The aim of this study is to explore the genetic information associated with the development of TAA and aAD in individuals without history or syndromic features (Marfan syndrome, Ehlers-Danlos syndrome, Turner syndrome etc.) for aortic disease. For this purpose, whole genome sequencing will be performed in patients with documented aortic aneurysm or\u002Fand aortic dissection.",[273,27],"Acute Aortic Dissection","2025-05-15",{"date":276,"type":38},"2025-05-16",{"date":278,"type":38},"2024-04-08",{"date":280,"type":20},"2028-12-31",{"name":282,"class":45},"University Hospital, Basel, Switzerland",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":88,"phases":4,"briefSummary":293,"conditions":294,"keywords":299,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":55},"100555113","post-market-registry-for-gore-tag-thoracic-branch-endoprosthesis-100555113","NCT06507865","Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis","Characterization of Mid-term Post Market Clinical Follow Up of GORE® TAG® Thoracic Branch Endoprosthesis Facilitated Aortic Arch and Descending Aorta Intervention","Inclusion Criteria:\n\nPatient or legally authorized representative (LAR) provides written authorization and\u002For consent per institution and geographical requirements Patient has been or is intended to be treated with an eligible registry device Patient is age ≥ 18 years at time of informed consent signature.\n\nExclusion Criteria:\n\nPatient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.\n\nPatient with exclusion criteria required by local law. Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.",{"count":291,"type":20},200,"2 Years","The goal of this observational study is to collect mid-term post-market clinical follow-up data of GORE® TAG® Thoracic Branch Endoprosthesis used according to the standard medical practice in patients presenting with vascular disease. This registry aims to answer questions related to the efficacy and safety of GORE® TAG® Thoracic Branch Endoprosthesis.",[295,296,297,27,298],"Aneurysm","Dissection, Aortic","TAA Thoracoabdominal Aortic Aneurysm","Transection Aorta",[300,295,301,302,303,304],"TEVAR","Dissection","Aorta","Endovascular stent graft","Thoracic branch endoprosthesis","2025-05-05",{"date":307,"type":38},"2025-05-09",{"date":309,"type":38},"2025-02-20",{"date":311,"type":20},"2031-04",{"name":74,"class":75},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":46},"100583948","active-thoracic-compromised-distal-landing-in-tevar-100583948","NCT06882967","Active Thoracic Compromised Distal LANding in TEvar","Thoracic Endovascular Aortic Repair in Compromised Distal Landing Zones","ATLANTE","Inclusion Criteria:\n\n* Patients with descending thoracic aortic aneurysms (DTAAs) with a maximal aortic diameter \\> 55mm or rapid growth (\\>10mm \u002F year).\n* Patients presenting with at least 2 cognizable features related to an adverse aortic morphology will be considered for inclusion. The following features will be evaluated for the inclusion: distal LZ length ≤25-mm, distal LZ diameter ≥38-mm, LZ conical morphology, distal descending thoracic aorta angulation ≤116° or tortuosity index ≥1.4\n\nExclusion Criteria:\n\n* Emergency setting, including hemodynamic instability at time of enrollment\n* Patients with aortic dissection pathology",{"count":291,"type":20},"Thoracic endovascular aortic repair (TEVAR) has become the mainstay of aortic intervention for descending thoracic aortic pathology. Its durability hinges on achieving adequate seal in the endograft landing zones (LZs), with the distal LZ largely understudied. Only recently are suboptimal distal LZs receiving attention for their role in major complications including stent graft migration, type 1B endoleaks, and distal stent graft-induced new entry tears, all of which can contribute to further aortic degeneration. The thoracic distal LZ. When a short distal LZ was reported, the distal endoleak rate ranged from 3.5% to 33%. This led to reintervention in 19%, along with coverage of the celiac trunk in more than half of short LZ cases.\n\nThe objective of this study was to evaluate the outcomes of TEVAR patients with compromised distal landing zone (CDLZs) treated with distal active fixation stent-grafts (DAFs), distal scallop stent-grafts, distal Aptus Heli-FX EndoAnchors, and standard stent-grafts.",[27,324],"Aortic Diseases","2025-03-15",{"date":327,"type":38},"2025-03-19",{"date":329,"type":38},"2022-11-01",{"date":331,"type":20},"2027-11-01",{"name":333,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":46},"100498992","mid--and-long-term-outcomes-of-custom-made-aortic-devices-100498992","NCT05777460","Mid- and Long-term Outcomes of Custom-made Aortic Devices","Results From a Multicenter Registry on the Outcomes of the Terumo Custom-made Aortic Endograft","Inclusion Criteria:\n\n* Thoracic Aortic Disease\n\nExclusion Criteria:\n\n* Urgent\u002FEmergent treatment",{"count":342,"type":20},60,"This study aims to evaluate mid- and long-term outcomes after Thoracic endovascular aortic repair (TEVAR) with custom-made devices.",[324,27],{"date":346,"type":38},"2025-03-18",{"date":348,"type":38},"2020-10-01",{"date":331,"type":20},{"name":333,"class":45},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":359,"targetDuration":360,"studyType":88,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":46},"100402718","trajectory-of-neuroinflammatory-markers-in-cerebrospinal-fluid-prior-to-and-after-thoracic-aortic-surgery-100402718","NCT04523909","Trajectory of Neuroinflammatory Markers in Cerebrospinal Fluid Prior to and After Thoracic Aortic Surgery","Trajectory of Neuroinflammatory Markers in Cerebrospinal Fluid Prior to and After Thoracic Aortic Surgery: the TURBO Study","TURBO","Inclusion Criteria:\n\n* Competent patients ≥ 18 years\n* Patients who will undergo thoracic aortic surgery and will therefore receive an external lumbar drain as a standard of care procedure.\n\nExclusion Criteria:\n\n* Patients with meningitis\u002Fencephalitis\u002Fbrain abscess within the last 6 months\n* Patients with other neurological conditions: brain injury (acute stroke, brain trauma or cerebral haemorrhage) within the last 3 months, known brain tumours, neurodegenerative disease or known pre-existing cognitive impairment (to a degree that would be compatible with mild cognitive impairment or more).\n* Brain or spinal surgery within the last 3 months\n* Active infection \\\u003C2 weeks before surgery\n* Patients who object against storage of their body material for scientific reasons",{"count":224,"type":20},"2 Weeks","Observational prospective pilot study to analyze the trajectory of neuroinflammatory protein expression in cerebrospinal fluid (CSF) in relation to systemic compartment in patients undergoing thoracic aortic surgery.\n\nThe aim of this study is to identify and unravel the biochemical (neuroinflammatory) pathways involved in postoperative delirium.\n\nPatient undergoing thoracic aortic surgery will have an external lumbar drain (ELD) in situ on the day before surgery. This ELD remains in place during and three days after surgery to reduce the risk on periprocedural spinal cord ischemia. Paired measurements of CSF and blood will be analyzed.",[363,364,27],"Postoperative Delirium","Postoperative Cognitive Dysfunction","2023-03-28",{"date":367,"type":38},"2023-03-31",{"date":369,"type":38},"2017-12-18",{"date":371,"type":20},"2026-12-01",{"name":373,"class":45},"Radboud University Medical Center",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":380,"enrollmentInfo":381,"targetDuration":382,"studyType":88,"phases":4,"briefSummary":383,"conditions":384,"keywords":390,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":46},"100463055","endobarc-s-study-endovascular-branched-stent-grafts-for-aortic-arch-pathologies-in-spain-100463055","NCT05309707","ENDOBARC-S Study: \"Endovascular Branched Stent-grafts for Aortic ARCh Pathologies in Spain\"","Inclusion Criteria:\n\n* Patient is between 18 and 90 years old\n* Patient with aortic arch pathologies (aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma), treated by branched stent-grafts (Nexus stent graft system©, Relay® Branch or Zenith arch branch graft®, with proximal landing at zone 0.\n* Patient must be available for the appropriate follow-up times for the duration of the study\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Patient less than 18 years old or more than 90 years old.\n* Patient has allergies to materials necessary for endovascular repair (e.g. contrast media, anticoagulants or heparin, nitinol, polyester, gold, platinum-iridium)\n* Patient has systemic infection or suspected systemic infection\n* Patient has thrombocytopenia (platelet count \\\u003C 150000\u002Fµl)\n* Patient has untreated hyperthyroidism\n* Patient has a progressive or untreated malignancy.\n* Patient is pregnant or breastfeeding.\n* Patient has a life expectancy of less than 1 year.\n* Not informed consent signed","90 Years",{"count":224,"type":20},"5 Years","The ENDOBARC-S post-market clinical follow-up study is undertaken to evaluate the prevention of death related to aortic arch pathologies when treated by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.\n\nThe secondary objective is to evaluate the safety and clinical performance of the studied devices.",[27,61,385,386,387,324,388,389],"Stent-Graft Endoleak","Stent-Graft Stenosis","Intramural Hematoma","Cardiovascular Diseases","Vascular Diseases",[302,92,391,392],"Thoracic aorta dissection","Endovascular repair","2022-03-24",{"date":395,"type":38},"2022-04-04",{"date":397,"type":38},"2022-01-01",{"date":399,"type":20},"2027-12-31",{"name":401,"class":402},"Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","NETWORK"]